Page 12 - Inaugural HKU Urology Congress program book (high resolution) 2026 0723
P. 12
LOCAL FACULTY LOCAL FACULTY
BIOGRAPHY BIOGRAPHY
Steve Wai-Hee Chan Peter Ka-Fung Chiu
Dr. Steve Wai-Hee Chan graduated from The University of Hong Kong in 1992 and Dr. Peter Ka-Fung Chiu is Associate Professor at The Chinese University of Hong Kong,
became a specialist in urology in 1998. He completed his Master's Degree in Health and with primary clinical and research interests in prostate cancer and benign prostatic
Hospital Management at the University of Birmingham in 2003. Dr. Chan was Consultant hyperplasia. For prostate cancer, he has conducted studies in novel diagnostic modalities
Urologist at Caritas Medical Centre and later as Head and Consultant of the Division of including blood biomarker prostate health index (phi), urine biomarker spermine, and
Urology at Queen Elizabeth Hospital until July 2013. He is currently Associate Director of transperineal MRI-ultrasound fusion biopsy. He was involved in the initiation of focal
the Urology Centre at Hong Kong Sanatorium and Hospital. therapy services (HIFU and cryotherapy) for prostate cancer in Hong Kong and is principal
investigator of a phase 2 clinical trial on Targeted Microwave Ablation (TMA) for prostate
Dr. Chan is a past-President of the Hong Kong Urological Association and the Hong Kong cancer.
Society of Endourology. His main clinical and research interests are in robotic urological
surgery, especially prostatectomy and minimally invasive surgical management of benign For treatment of benign prostatic hyperplasia, Dr. Chiu has led research on water vapour
prostatic enlargement and prostate cancer. thermal therapy (Rezūm), prostate artery embolization (PAE), and GreenLaser and
BlueLaser vaporization. His work has been funded by over US$23.7 million in research
grants. He has published more than 215 peer-reviewed articles in leading journals such as
European Urology, European Urology Oncology, Journal of Urology, BJU International, and
Prostate Cancer and Prostatic Diseases.
Dr. Chiu is a pioneer in the development of new robotic and therapeutic devices. He is
principal investigator of the first-in-human trial of the Agilis Intilume system, an endoscopic
robotic system with two flexible arms for transurethral bladder surgery, since 2024. He
has also participated in first-in-human trials of the Da Vinci SP system (2017), Targeted
Microwave Ablation (2019), Cornerstone Robotics (2022), and Prostate Histotripsy (2026).
10 11
